ClinicalTrials.gg
Not yet recruitingNCT06244862JAKAHDIUpdated Feb 6, 2024

JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit

A Phase 2 interventional study of Ruxolitinib in Hemophagocytic Syndromes, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-02-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic — 5 open to participants now, 6 under way, none of them phase 3. ruxolitinib · Lymphohistiocytosis, Hemophagocytic.

Planned enrollment
5th of 10
42 · median 36
Started
2024
with 2 others
Phase 2
4 of 10
3 open now
Registered
9th of 10
by date
Lead sponsor
2 of 10
Assistance Publique - Hôpitaux de Paris

Among the 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic, this one is the 5th largest by planned enrollment, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 9th registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

5 of the 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic, or all of them as a file.
02

Study summary

Hemophagocytic syndrome (HS) is a rare condition that can be responsible for severe organ failure. Therapeutic guidelines are mainly based on observational studies and expert opinions: no therapeutic advance has been developed for years, explaining why mortality in HS remains high (Intensive Care Unit mortality ranging from 40 to 70%). If etoposide remains the gold standard in critically ill HS patients, nearly 20% of patients are refractory to this therapy: treatment escalation is common, most often requiring the administration of intensive treatments generating high toxicity. Ruxolitinib is the first approved JAK inhibitor. It has been associated with improvement of HS manifestations and survival in a pre-clinical murine model. Data in humans are scarce but promising.

The aim is to demonstrate that ruxolitinib, in association with standard of care, may reverse organ failure (as represented by Sequential Organ Failure Assessment (SOFA) score) better than standard of care alone in critically ill patients with acquired HS.

03

Conditions studied

  • Hemophagocytic Syndromes
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients older than 18 years
  • acquired hemophagocytic syndrome, regardless of etiology, defined by the presence of 5 or 6 HLH-2004 criteria or HScore ≥ 200
  • admission in the ICU
  • need for symptomatic treatment of HS in relation with organ failure, as defined by SOFA score ≥ 4
  • signed:

    • by the patient,
    • Or informed consent signed by a family members/trustworthy person if his condition does not allow him to express his consent in written
  • Or in an emergency situation and in the absence of family members/trustworthy person, the patient can be enrolled. The consent to participate to the research will be requested as soon as the condition of the patient will allow).
  • The inclusion of women of requires the use of a highly effective measure. Contraception should be maintained during treatment and one day after

Exclusion criteria

Exclusion Criteria:

  • Moribund, defined by a \< 48 hours;
  • Pregnant or lactating patients (women of must have a negative urine or blood Human Chorionic Gonadotropin pregnancy test prior to trial entry);
  • No affiliation to health insurance;
  • Known to ruxolitinib;
  • Lactose intolerance;
  • Hypersensitivity to cellulose, microcrystalline; magnesium stearate; silica, colloidal anhydrous; sodium starch glycolate (Type A); povidone K30; hydroxypropylcellulose 300 to 600 cps,
  • Pre-existing decisions of withholding/withdrawing care,
  • History of progressive multifocal leukoencephalopathy
  • Uncontrolled cutaneous cancer
  • Persons under psychiatric care that would impede understanding of and optimal treatment and follow-up
  • Adults subject to a legal protection measure (guardianship, curatorship and safeguard of justice)
  • Patients deprived of their liberty by a judicial or administrative decision
  • Participation in another interventional research
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Interventional medicinal product

    Drug: Ruxolitinib

Interventions

  • Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.

06

What researchers measure

Primary outcomes

  1. Survival with a decrease in SOFA score ≥ 3 points

    Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function.

    Time frame: At day 7

Secondary outcomes

  1. Overall survival in HS critically ill patients

    Time frame: At 6 months

  2. SOFA score

    Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function.

    Time frame: At day 1

  3. SOFA score

    Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function.

    Time frame: At day 14

  4. SOFA score

    Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function.

    Time frame: At day 28

  5. Length of stay in Intensive Care Unit

    number of days in the ICU from inclusion to ICU discharge or death

    Time frame: Up to 6 months

  6. Hospital length of stay

    number of days in the hospital from inclusion to hospital discharge or death

    Time frame: Up to 6 months

  7. Measurement of clinical and biological manifestations

    Measurements of temperature, ferritin level, CD25 soluble receptor dosage, fibrinogen level, triglycerides level, haemoglobin level, white blood cells count, platelets count

    Time frame: At day 1

  8. Measurement of clinical and biological manifestations

    Measurements of temperature, ferritin level, CD25 soluble receptor dosage, fibrinogen level, triglycerides level, haemoglobin level, white blood cells count, platelets count

    Time frame: At day 7

  9. Measurement of temperature

    Time frame: At day 14

  10. Measurement of temperature

    Time frame: At day 28

  11. Measurement of ferritin level

    Time frame: At day 14

  12. Measurement of ferritin level

    Time frame: At day 28

  13. Measurement of CD25 soluble receptor dosage

    Time frame: At day 14

  14. Measurement of CD25 soluble receptor dosage

    Time frame: At day 28

  15. Measurement of fibrinogen level

    Time frame: At day 14

  16. Measurement of fibrinogen level

    Time frame: At day 28

  17. Measurement of triglycerides level

    Time frame: At day 14

  18. Measurement of triglycerides level

    Time frame: At day 28

  19. Measurement of haemoglobin level

    Time frame: At day 14

  20. Measurement of haemoglobin level

    Time frame: At day 28

  21. Measurement of white blood cells count

    Time frame: At day 14

  22. Measurement of white blood cells count

    Time frame: At day 28

  23. Platelets count

    Time frame: At day 14

  24. Platelets count

    Time frame: At day 28

  25. Dosages of IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha

    Time frame: At day 1

  26. Dosages of IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha

    Time frame: At day 7

  27. Dosages of IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha

    Time frame: At day 14

  28. Dosages of IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha

    Time frame: At day 28

  29. Incidence of nosocomial infections (viral and bacterial)

    Time frame: Until day 28

  30. Incidence of adverse event, severe adverse event

    Intensity and frequency of adverse event and severe adverse event according to the CTCAE Toxicity Grading Scale for Determining The Severity of Adverse Events

    Time frame: Until day 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2024; primary completion for Aug 2025, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2023
First posted
Feb 6, 2024
StartEst.
Feb 1, 2024
Primary completionEst.
Aug 8, 2025
CompletionEst.
Feb 1, 2026
Last update
Feb 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06244862
Responsible party
Sponsor
First posted
Feb 6, 2024
Start date
Feb 1, 2024 (estimated)
Primary completion
Aug 8, 2025 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Feb 6, 2024

Study contacts

Sandrine Valade, Dr
Contact
sandrine.valade@aphp.fr
+33142499419
Jérôme Lambert, Pr
Contact
jerome.lambert@u-paris.fr
+33142499742

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion